Quantum Biopharma (NASDAQ:QNTM) Announces Quarterly Earnings Results

Quantum Biopharma (NASDAQ:QNTM) issued its quarterly earnings results on Friday. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.05), Zacks reports.

Quantum Biopharma Trading Up 3.7%

QNTM traded up $0.32 during trading on Friday, hitting $8.91. 40,765 shares of the company’s stock were exchanged, compared to its average volume of 73,794. Quantum Biopharma has a 1 year low of $2.70 and a 1 year high of $38.25. The stock has a 50 day moving average price of $15.04 and a 200 day moving average price of $16.64. The firm has a market cap of $34.04 million, a P/E ratio of -0.64 and a beta of 0.54.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Wall Street Zen lowered Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Quantum Biopharma currently has a consensus rating of “Sell”.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.